Navigation Links
The Quantum Group Announces Exclusive Screening of New PWeR(TM) System
Date:7/29/2008

and, consequently, actual results may differ materially from those expressed or implied by these forward-looking statements. Such risk factors include, without limitation, the ability of the Company to properly execute its business model, to raise substantial and immediate additional capital to implement its business model, to attract and retain executive, management and operational personnel, to execute additional contracts with payers, to expand the CHS network, to negotiate favorable current debt and future capital raises, to negotiate favorable agreements with a diversified provider base and to continue to supply the services needed by its HMO clients as well as physician clients. The Company does not undertake any obligation to publicly update any forward-looking statements. There can be no assurance that the provisional patents discussed in this press release will be granted by the US Patent and Trademark Office, or, if they are granted, they will not be challenged by third parties, or if not that we will be able to effectively use or commercialize such patents and/or we may not have the resources to deploy such technology. As a result, investors should not place undue reliance on these forward-looking statements.

FOR MORE INFORMATION, PLEASE CONTACT:

PR Financial Marketing

Jim Blackman: 713-256-0369

jim@prfmonline.com

Or

Danielle Amodio

Vice President Corporate Communications

The Quantum Group, Inc.

561.798.9800


'/>"/>
SOURCE The Quantum Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. The Quantum Group Files TPA Application
2. The Quantum Group Expands Payer Partnerships
3. The Quantum Group Adds New Insurance Product for Physicians
4. The Quantum Group of Companies Exhibits at Statewide Medical Conference
5. Gene silencer and quantum dots reduce protein production to a whisper
6. The Quantum Group Announces Second Quarter Financial Results for Fiscal Year 2008
7. Microwave synthesis connects with the (quantum) dots
8. The Quantum Group & IBM Sign Research Collaboration Agreement for the LA Grid University Consortium
9. The Quantum Group Completes Corporate Expansion Plan; Employee and Corporate Office Growth Leads the Way for Enhanced Innovation and Growth Through 2009
10. The Quantum Group Announces Web-Based Portal for Physicians
11. The Quantum Group Executes First Medicaid Service Contract with HMO
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6Daniel K. Spiegelman Elected to Board of Directors of Omeros 2Shanghai ChemPartner Is Pleased to be Part of Agios' Groundbreaking Cancer Research 2Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17 2009 6162 1Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17 2009 6162 2Shire Re Launches FOCUS an Online Personalized Patient Support Program for Adults with ADHD Taking Vyvanse 28R 29 28lisdexamfetamine dimesylate 29 6160 1Shire Re Launches FOCUS an Online Personalized Patient Support Program for Adults with ADHD Taking Vyvanse 28R 29 28lisdexamfetamine dimesylate 29 6160 2Shire Re Launches FOCUS an Online Personalized Patient Support Program for Adults with ADHD Taking Vyvanse 28R 29 28lisdexamfetamine dimesylate 29 6160 3Shire Re Launches FOCUS an Online Personalized Patient Support Program for Adults with ADHD Taking Vyvanse 28R 29 28lisdexamfetamine dimesylate 29 6160 4Shire Re Launches FOCUS an Online Personalized Patient Support Program for Adults with ADHD Taking Vyvanse 28R 29 28lisdexamfetamine dimesylate 29 6160 5Natural Alternatives International Inc Announces Filing of Patent Infringement Lawsuit 6158 1Natural Alternatives International Inc Announces Filing of Patent Infringement Lawsuit 6158 2